Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $7
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $9 to $7.
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $9 to $7.